What is Cerus?
Headquartered in Concord, California, Cerus is primarily recognized for the development and commercialization of the INTERCEPT Blood System. This sophisticated pathogen reduction technology is designed to inactivate viruses, bacteria, and parasites in blood components, including platelets and plasma. By providing a robust defense against transfusion-transmitted infections, the company serves a vital role in the healthcare ecosystem. Beyond its core offerings, Cerus maintains an active research and development pipeline, with ongoing programs focused on red blood cell safety, further expanding its footprint in the global blood banking market.
How much funding has Cerus raised?
Cerus has raised a total of $378.6M across 8 funding rounds:
Stock Offering
$21.3M
Debt
$10M
Debt
$30M
Debt
$40M
Debt
$90M
Stock Offering
$63.3M
Unspecified
$14M
Debt
$110M
Stock Issuance/Offering (1997): $21.3M with participation from Undisclosed
Debt (2010): $10M led by Oxford Finance Corporation
Debt (2014): $30M supported by Oxford Finance
Debt (2017): $40M featuring Oxford Finance Corporation
Debt (2019): $90M backed by MidCap Financial
Stock Issuance/Offering (2020): $63.3M with participation from Undisclosed
Unspecified (2020): $14M led by Biomedical Advanced Research and Development Authority
Debt (2026): $110M supported by MidCap Financial
Key Investors in Cerus
MidCap Financial
A specialty finance firm that provides flexible, asset-based lending solutions tailored to the unique needs of healthcare and life sciences enterprises.
Oxford Finance Corporation
A dedicated specialty finance firm offering customized financial solutions to support the growth and operational requirements of healthcare and life sciences companies worldwide.
Biomedical Advanced Research and Development Authority
A federal agency focused on the advanced research and development of medical countermeasures to protect the nation from health security threats.
What's next for Cerus?
With the successful closure of this major strategic investment, Cerus is well-positioned to accelerate its commercial expansion and deepen its R&D initiatives. The capital will likely be deployed to scale the adoption of the INTERCEPT Blood System across international markets and advance clinical programs for red blood cell applications. As the company transitions into this next phase of growth, the focus remains on operational efficiency and the continued integration of its technology into standard blood center protocols. This financial milestone provides the necessary runway to navigate the complexities of the global healthcare landscape while maintaining a competitive edge in pathogen reduction innovation.
See full Cerus company page
